Related Experiment Videos
[Primary myelodysplastic syndrome in children]
Srpski Arhiv Za Celokupno Lekarstvo
|January 11, 2005
Summary
Primary Myelodysplastic Syndromes (MDS) in children are serious blood disorders. Bone marrow transplantation is the only effective treatment, as other therapies and prognostic factors show limited significance.
Area of Science:
- Hematology
- Pediatric Oncology
- Stem Cell Transplantation
Context:
- Primary Myelodysplastic Syndromes (MDS) are heterogeneous clonal hematopoietic disorders in children.
- MDS can progress to acute myeloid leukemia or lead to fatal infections and hemorrhage.
- Current conservative management strategies are largely unsuccessful.
Purpose:
- To review the clinical and hematological presentations, dysplastic features, and histological and cytogenetic findings in 29 children with primary MDS.
- To evaluate the significance of prognostic factors in pediatric MDS.
- To underscore the role of bone marrow transplantation in treating pediatric MDS.
Summary:
- A review of 29 pediatric primary MDS cases revealed common indications for evaluation including cytopenias, fever, and infections.
- Hepatosplenomegaly (65%), normochromic anemia (86%), and thrombocytopenia (76%) were frequent findings.
- Pancytopenia was associated with lower survival, but dysplasia, histology, and karyotype did not significantly influence outcomes.
Impact:
- Prognostic factors in pediatric MDS have limited significance.
- Bone marrow transplantation is the definitive treatment for pediatric MDS.
- Early identification and transplantation are crucial for improving outcomes in children with MDS.